LOI Deadline: May 24, 2021

Please see the opportunity page for LOI instructions: https://ima.stanford.edu/funding-opportunities/high-throughput-small-molecule-screening-spring-2021

Submit LOIs through the application portal: https://chemh.slideroom.com/#/permalink/program/60425

Purpose and Scope: The Stanford Innovative Medicines Accelerator (IMA) aims to accelerate the translation of scientific discoveries at Stanford University into new therapeutics that impact human health. Adaptation of laboratory-grade assays to high-throughput screening formats is a key bottleneck in this process. IMA is accepting proposals for assay development projects to create and optimize miniaturized assays in 384-well microplate format for use in high-throughput, small-molecule screens. Competitive projects will have a strong, novel therapeutic hypothesis and aim to identify small molecule leads for a molecular target or cellular phenotype. Projects that aim to develop an assay that is not highly scalable to screen a few thousand compound clinical collection will also be considered. More than one-half of the projects selected by this program last fall have successfully miniaturized their assays and are on track to run a high-throughput screen.

Support Provided: Selected projects will receive access to the IMA High-Throughput Screening Knowledge Center (HTSKC) facility, which includes instrumentation fees, associated consumables, and expert training and advice in assay development for high-throughput screens (384-well microplate format).

It is anticipated that most selected projects will receive in-kind support for ~6 months with critical go/no-go decision points defined for this project period. The specific level of support will vary by project need. Projects with successful outcomes will be eligible for continued support from the HTSKC for a high-throughput screen.

Eligibility: All Stanford faculty with PI eligibility are welcome to apply.

Timeline: Selection of LOIs is estimated to be completed by late June, 2021. The submission deadline for full proposals will be mid-July, 2021. Final decisions on full proposals will be made by late August, 2021.

Contact: For questions about the funding opportunity, please contact the program manager:

Sachin Jadhav, Ph.D.

Program Manager, Stanford IMA

ssjadhav@stanford.edu

Submission timeline: May 5, 2021 (open) - June 16, 2021 (deadline)

The Emerson Collective Cancer Research Fund is requesting individual or team proposals for research projects relate to the following topic areas:

• Engineering allogeneic cells with new properties to:

• prevent their recognition by the host immune system;
• promote their persistence in the host;
• defeat suppressive mechanisms of the tumor microenvironment;
• synergize with host innate and adaptive immune systems; and/or,
• allow gating or other regulation of their functions temporally or
• geographically to improve potency or reduce toxicity.
• Validating new target antigens for cell therapy in cancer
• Targeted intracellular gene or protein delivery mechanisms
• Enabling early cancer detection

Positive criteria include the potential of a project to significantly impact our understanding of and/or approaches to the prevention, diagnosis, or treatment of cancer. This RFA is open to all faculty and trainees sponsored by faculty undertaking research relevant to cancer at the above eligible sites. Awards range from 1 to 2 years, $50,000 minimum to $400,000 maximum, which must include both direct and indirect costs. Emerson Collective and associates will evaluate applications on the following positive criteria:

• The audacity and innovation of the research proposal
• The potential of the proposed research to affect multiple cancer types
• The potential to translate said research into further experiments, and clinical trials
• The applicant’s lack of resources to pursue the proposed research
• Compliance with a two-year maximum timeframe for research

Please note: The applicant’s prior experimental track record will not be the principal determining factor in evaluation. This fund does not support incremental research. Emerson Collective evaluates the applicant’s current and pending support. Duplication of proposed science is grounds for Emerson Collective to return the proposal without review.

Submission portal website:

https://echealthgrants.smapply.io/prog/emerson_collective_cancer_research_fund/

Questions about submitting in Survey Monkey Apply? Please contact

healthgrants@emersoncollective.com

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications to develop, adapt, and test individual-, community- or multilevel interventions to address modifiable risk factors for cancer in rural populations. Applications should focus on primary prevention and assess and address one or more of the social and behavioral risk factors that contribute to cancer disparities in rural populations: tobacco use; diet, physical activity and weight; alcohol use; UV exposure; and HPV vaccination. Applications should also assess and address myriad social determinants of health, cultural factors, and health care and technology access barriers that may contribute to rural cancer disparities. This FOA also encourages implementation science research, to incorporate efficacious cancer control interventions in a coordinated way, into broader, sustainable health programs that are designed to reach rural populations and allow local customization and adaptation.

Deadline: March 15, 2021; January 18, 2022

Read more or apply >>

This Request for Applications is associated with the Partnership for Accelerating Cancer Therapies (PACT), a project associated with the Beau Biden Cancer Moonshot ™ Initiative that is intended to accelerate cancer research.The overall goal for this Request for Applications (RFA) is to solicit clinical trials to partner with the PACT initiative to provide biospecimens for exploratory deep immunoprofiling analysis, employing this standardized set of biomarker assays. More information >>

The PACT partnership will consider supporting the deployment of the selected standardized biomarker assays in a broad range of IO trials. The group is encouraging trials from any cancer type that is comparing effects of immune therapy or immune therapy in combinations with another therapy. Examples of IO considered include, but are not limited to:

• Immune Checkpoint Inhibitors (ICIs)
• Other immune modulators
• Immunotherapy in combination immune modulators, targeted agents or chemotherapy/radiotherapy
• Adoptive Cell Therapy
• Immune vaccine therapies

Applications will be reviewed on a rolling basis and in order of submission. All applications must be received prior to January 31, 2022.

On October 30, 2017 the National Cancer Institute is pleased to announce the release of 17 new Cancer Moonshot funding opportunities. As you know, efforts supported through the Cancer Moonshot aim to accelerate cancer research, making more therapies available to patients and improving the ability to prevent cancer and detect it the earliest stage possible.

Following receipt of the Blue Ribbon Panel report, NCI identified funding opportunity announcements (FOAs) from within its extensive research portfolio that address the goals of the Cancer Moonshot. These opportunities mark the beginning of a growing Cancer Moonshot portfolio which will continue to expand given the authorization of the 21st Century Cures Act to fund the Beau Biden Cancer Moonshot with $1.8 billion over 7 years. While the FOAs listed below highlight research initiatives that align with the efforts of the Cancer Moonshot, they may be supported with existing funds or with the 21st Century Cures funding.

On October 30, 2017 the National Cancer Institute is pleased to announce the release of 17 new Cancer Moonshot funding opportunities. As you know, efforts supported through the Cancer Moonshot aim to accelerate cancer research, making more therapies available to patients and improving the ability to prevent cancer and detect it the earliest stage possible. Learn more about these opportunities here.

Cancer Moonshot - UPDATED Funding Opportunities link